Analytical Data
-
Gene name
WAS
- Application
-
Alternative Names
Wiskott-Aldrich syndrome protein(WASp)
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P42768
-
Expression Region
2-502aa
-
Molecular Weight
53.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
WAS (Wiskott-Aldrich Syndrome) protein is an essential cytoskeletal regulator involved in immune cell function, particularly in T cells and platelets. Mutations in the WAS gene lead to Wiskott-Aldrich Syndrome, a rare X-linked immunodeficiency characterized by eczema, recurrent infections, and thrombocytopenia. The importance of WAS protein in immune responses has driven extensive research into its structure and function. Understanding the mechanisms by which WAS protein affects actin dynamics is crucial for unraveling how its dysfunction leads to the clinical manifestations of the syndrome. Additionally, studies on WAS protein have implications for gene therapy and potential treatments for related immune disorders. Recent advancements in recombinant protein technology have facilitated the production of WAS protein, allowing researchers to explore its role in cellular processes and its potential as a therapeutic target. By investigating WAS protein's interactions and pathways, scientists aim to develop new strategies for managing Wiskott-Aldrich Syndrome and enhancing our knowledge of immune system regulation.
